The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the plasmid dna manufacturing market in recent years?
The growing acceptance of gene therapy is expected to propel the growth of the plasmid DNA manufacturing market going forward. Gene therapy refers to a medical treatment that involves modifying or manipulating a person’s genes to treat or prevent disease. Gene therapy is on the rise due to advancements in genetic engineering technologies, increasing investment in research and development, successful clinical trials, and the growing prevalence of genetic disorders, which together highlight its potential for providing long-term or permanent cures. Plasmid DNA manufacturing is essential for gene therapy as it produces the vectors needed to deliver therapeutic genes into cells, facilitating the treatment of genetic disorders. For instance, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, the number of gene therapies in Phase III clinical trials grew by 10% in Q3 2023, the first quarterly increase since Q3 2022. Therefore, the growing acceptance of gene therapy is driving the growth of the plasmid DNA manufacturing market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=15895&type=smp
What is the projected market size of the plasmid dna manufacturing industry, and how is it expected to grow?
The plasmid DNA manufacturing market size has grown exponentially in recent years. It will grow from $2.34 billion in 2024 to $2.9 billion in 2025 at a compound annual growth rate (CAGR) of 23.9%. The growth in the historic period can be attributed to the application of plasmid DNA in industrial processes, the use of plasmid DNA in creating genetically modified organisms, the production of monoclonal antibodies using plasmid DNA in cell lines, international health initiatives, plasmid DNA is used in bioremediation and other environmental applications and microbiome studies.
The plasmid DNA manufacturing market size is expected to see exponential growth in the next few years. It will grow to $6.78 billion in 2029 at a compound annual growth rate (CAGR) of 23.6%. The growth in the forecast period can be attributed to the increasing use of plasmid DNA in the development of DNA vaccines for infectious diseases, increasing adoption of plasmid DNA in the development of antibody-drug conjugates, personalized therapies, the use of plasmid DNA in developing cancer treatments and intellectual property developments. Major trends in the forecast period include increasing activity in licensing agreements for plasmid DNA technologies, customized solutions, cost reduction strategies, high-throughput screening, and the development of scalable manufacturing solutions.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=15895&type=smp
Who are the key players driving competition in the plasmid dna manufacturing market?
Major companies operating in the plasmid DNA manufacturing market are Thermo Fisher Scientific Inc., Eurofins Genomics LLC, Catalent Inc., Charles River Laboratories, Recipharm AB, Kaneka Corp., Genscript Biotech Corporation, Aldevron LLC, Genewiz, OriGene Technologies, Celonic AG, Creative Biogene, Cellectis, Synbio Technologies, VectorBuilder Inc., Altogen Biosystems, Addgene, Andelyn Biosciences, AGC Biologics, VGXI, BioCat GmbH, GeneCopoeia, PlasmidFactory GmbH & Co. KG, Akron Biotech, PackGene Biotech lnc.
What key trends are expected to drive the plant-based food packaging market during the forecast period?
Major companies operating in the plasmid DNA manufacturing market are developing advanced bioprocessing technologies to enhance the efficiency, scalability, and quality of plasmid DNA production. These innovations aim to streamline the manufacturing process, reduce production costs, and ensure that the plasmid DNA meets stringent regulatory standards for therapeutic applications. For instance, in January 2023, Charles River Laboratories, a US-based pharmaceutical company, launched eXpDNA platform, designed for the efficient production and purification of high-quality plasmid DNA. This platform integrates advanced bioprocessing technologies, scalable production methods, and rigorous quality control measures to produce plasmid DNA that meets the stringent requirements for therapeutic and clinical applications. The eXpDNA platform is used extensively in gene therapy, DNA vaccine development, and other biopharmaceutical applications that demand high yield, purity, and consistency.
Which key geographies are driving the growth of the plasmid dna manufacturing market?
North America was the largest region in the plasmid DNA manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasmid DNA manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/plasmid-dna-manufacturing-global-market-report
What are the key segments driving growth in the plasmid dna manufacturing market?
The plasmid DNA manufacturing market covered in this report is segmented –
1) By Grade: Research And Development Grade, Good Manufacturing Practice (GMP) Grade
2) By Development Phase: Pre-Clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics
3) By Disease: Infectious Disease, Cancer, Genetic Disorder, Other Diseases
4) By Application: Deoxyribonucleic Acid (DNA) Vaccines, Cell And Gene Therapy, Immunotherapy, Other Applications
Subsegments:
1) By Research And Development Grade: Small-scale Plasmid DNA Production, Preclinical Research Plasmid DNA
2) By Good Manufacturing Practice (GMP) Grade: Clinical Trial Material Production, Commercial-Scale Plasmid DNA Production
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15895
How is the plasmid dna manufacturing market defined, and what are its core characteristics?
Plasmid deoxyribonucleic acid (DNA) manufacturing refers to the process of producing large quantities of plasmid DNA molecules for use in various biotechnological applications, including gene therapy, molecular cloning, and the production of recombinant proteins. This process involves the growth of bacterial cells containing the desired plasmid DNA, followed by purification to isolate the plasmid DNA from other cellular components.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
